Overweight and ObesityNCT06789471
The Effects of Psyllium Seed on Body Weight and Metabolic Syndrome Indicators in Patients with Schizophrenia
A study testing psyllium husk in people with Overweight and Obesity and Metabolic Cardiovascular Syndrome, run by Ru-Shin Zhang at 1 site in Taiwan.
Trial summary
The research employs a quasi-experimental design, aiming to enroll 24 hospitalized patients with schizophrenia from 2hospitals in the central region, guided by G Power calculations. Participants will be carefully matched based on gender, age (within 5 years), and the same hospital. Read more about this study
- Who is it for?
- Ages 20 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Overweight and Obesity, Metabolic Cardiovascular Syndrome, Schizophrenia, Disorganized
- What is being tested?
- psyllium husk
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 24 participants
- Where
- 1 siteTaiwan
- Study dates
- 1 May 2024to 1 Oct 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Diagnosis of schizophrenia based on DSM-V criteria;
- Age between 20 and 65 years old
- Body mass index (BMI) of 24 kg/m² or higher or those who meet more than three indicators of metabolic syndrome
- Individuals with glycated hemoglobin (HbA1c) levels ranging from 5.7% to 6.4%.
Who cannot join
- Exclude those who use blood sugar-lowering, blood pressure-lowering, and blood-lipid-lowering drugs.
- Patients with major internal and external diseases such as cardiovascular disease, cancer, patients who have experienced neuropathic intestinal obstruction, patients after bariatric surgery, or those who have experienced choking.
- Those with obvious mental symptoms who are unable to cooperate.
- History of grain allergy, asthma, etc.
- Persons subject to a declaration of auxiliary guardianship.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Effects of Psyllium Seed on Body Weight and Metabolic Syndrome Indicators in Patients
The research employs a quasi-experimental design, aiming to enroll 24 hospitalized patients with schizophrenia from 2hospitals in the central region, guided by G Power calculations. Participants will be carefully matched based on gender, age (within 5 years), and the same hospital. They will be divided into two groups using a single-masked randomized allocation method. The experimental group (psyllium husk group) will consume 10 grams of psyllium husk daily, split into two doses, taken about an hour before meals. The control group will receive standard treatment. The intervention will last for 12 weeks.
Inclusion criteria involve a schizophrenia diagnosis as per DSM-V criteria, age between 20 and 65 years, and a body mass index (BMI) of 24 kg/m² or higher, or meeting more than three indicators of metabolic syndrome. Exclusion criteria include medications for glucose, blood pressure, or lipid levels reduction, significant comorbidities like cardiovascular diseases or cancer, a history of neurogenic bowel obstruction or post-weight loss surgery, and patients with severe psychiatric symptoms impeding cooperation.
Each patient will undergo measurements for weight, waist circumference, body mass index, and blood biochemical analysis, encompassing fasting blood glucose (FBG), total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and glycated hemoglobin (HbA1c) before the intervention and after 12 weeks.
Read the detailed description
The study adopts a quasi-experimental research design and plans to include 24 hospitalized patients with schizophrenia from 2 hospitals in the central region, based on G Power calculations. This study will be matched based on gender, age (within 10 years), and the same hospital.The participants will be divided into two groups using a single-masked randomized allocation method. The experimental group (psyllium husk group) will consume 10 grams of psyllium husk daily, divided into two doses, and taken approximately one hour before meals. The control group will receive standard treatment, and the intervention will last for 12 weeks. Inclusion criteria are: 1. Diagnosis of schizophrenia based on DSM-V criteria; 2. Age between 20 and 65 years old; 3. Body mass index (BMI) of 24 kg/m² or higher or those who meet more than three indicators of metabolic syndrome. Exclusion criteria are medications for lowering blood glucose, blood pressure, or lipid levels, significant comorbidities such as cardiovascular diseases or cancer, history of neurogenic bowel obstruction or post-weight loss surgery, and patients with prominent psychiatric symptoms who cannot cooperate. Each patient will undergo measurements of weight, waist circumference, body mass index, and blood biochemical analysis data, including fasting blood glucose (FBG), total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and glycated hemoglobin (HbA1c) before the intervention and after 12 weeks
- Being tested
- psyllium husk
- Medical subject headings
- Overweight, Obesity, Metabolic Syndrome, Schizophrenia, Disorganized
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
psyllium huskDietary supplement
Psyllium husk, derived from the seeds' husks of the Plantago ovata plant, is a plant-based fiber supplement.
| Study group | Role | What they receive |
|---|---|---|
| Psyllium group | Experimental | The experimental group (psyllium husk group) will consume 10 grams of psyllium husk daily, divided into two doses, and taken approximately one hour before meals for 12 weeks. Receives: Dietary Supplement: psyllium husk |
| Control group | No intervention | The control group will receive standard treatment, not use psyllium and the intervention will last for 12 weeks. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Body Weight in Kilograms
Measure body weight in the morning after waking up, with participants wearing light clothing and no shoes.
Measured: At baseline (week 0) and at weeks 6 and 12 of the study.
Waist Circumference in cm
Waist circumference will be measured to evaluate the impact of psyllium husk intervention on abdominal fat distribution in patients with schizophrenia. Measurements will be conducted using a flexible, non-stretchable measuring tape, positioned horizontally around the abdomen at the midpoint between the lower margin of the last palpable rib and the top of the iliac crest. Participants will stand upright, with feet close together, arms at their sides, and abdomen relaxed during the measurement. The values will be recorded in centimeters (cm). The experimental group will consume 10 grams of psyllium husk daily, while the control group will receive standard treatment. Changes in waist circumference will be analyzed within and between groups."
Measured: At baseline (week 0) and at weeks 6 and 12 of the study.
Body Mass Index (BMI) in (kg/m²)
Body mass index (BMI) will be calculated to evaluate the impact of psyllium husk intervention on overall body composition in patients with schizophrenia. BMI is expressed in kilograms per square meter (kg/m²) and will be calculated using the formula: weight (kg) divided by height squared (m²). Weight will be measured with a calibrated digital scale, ensuring participants wear light clothing and no shoes. Height will be measured using a wall-mounted stadiometer, with participants standing barefoot, heels together, arms at their sides, and head positioned in the Frankfurt horizontal plane. These measurements will be used to calculate BMI, which will be recorded and analyzed for changes within and between groups.
Measured: At baseline (week 0) and at weeks 6 and 12 of the study.
Secondary outcomes (1)
Metabolic syndrome indicators ex (Fasting Glucose (mg/dL) Total Cholesterol (mg/dL) Triglycerides (mg/dL) High-Density Lipoprotein Cholesterol (HDL-C, mg/dL) Low-Density Lipoprotein Cholesterol (LDL-C, mg/dL) Glycated Hemoglobin (HbA1c, %)
Each time, 5 c.c. of blood is drawn from the arm vein for the following tests and their respective units:
Fasting Glucose (mg/dL) Total Cholesterol (mg/dL) Triglycerides (mg/dL) High-Density Lipoprotein Cholesterol (HDL-C, mg/dL) Low-Density Lipoprotein Cholesterol (LDL-C, mg/dL) Glycated Hemoglobin (HbA1c, %) Blood collection requires at least 8 hours of fasting and is performed by professional medical technologists or nursing staff to ensure accurate results.
Measured: During weeks 0 and 12of the study
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jan 2025
- Study start1 May 2024
- Primary completion30 Sep 2024
- Study completion1 Oct 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Overweight and ObesityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- . This study will be matched based on gender, age (within 10 years), and the same hospital.The participants will be divided into two groups using a single-masked randomized allocation method. The experimental group (psyllium husk group) will consume 10 grams of psyllium husk daily, divided into two doses, and taken approximately one hour before meals. The control group will receive standard treatment, and the intervention will last for 12 weeks. Inclusion criteria are: 1. Diagnosis of schizophrenia based on DSM-V criteria; 2. Age between 20 and 65 years old; 3. Body mass index (BMI) of 24 kg/m² or higher or those who meet more than three indicators of metabolic syndrome. Exclusion criteria are medications for lowering blood glucose, blood pressure, or lipid levels, significant comorbidities such as cardiovascular diseases or cancer, history of neurogenic bowel obstruction or post-weight loss surgery, and patients with prominent psychiatric symptoms who cannot cooperate.
- Masking
- Single blind
- Who is masked
- Care provider
- Enrolment
- 24 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ru-Shin Zhang
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Ru-Shin Zhang, Hung Kaung University
- Investigators
- Mei-Ling Lin, Study director, HungKaungUniversity
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06789471
- Sponsor's protocol ID
- 112033
- Status last verified
- Nov 2024
- First submitted
- 23 Dec 2024
- Last updated
- 23 Jan 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effects of Psyllium Seed on Body Weight and Metabolic Syndrome Indicators in Patients
- ClinicalTrials.gov ID
- NCT06789471
- Acronym / sponsor ID
- 112033
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 24 participants (actual)
- Lead sponsor
- Ru-Shin ZhangUniversity, hospital or other
- Study start
- 1 May 2024 (actual)
- Primary completion
- 30 Sep 2024 (actual)
- Study completion
- 1 Oct 2024 (actual)
- First posted
- 23 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The research employs a quasi-experimental design, aiming to enroll 24 hospitalized patients with schizophrenia from 2hospitals in the central region, guided by G Power calculations. Participants will be carefully matched based on gender, age (within 5 years), and the same hospital. They will be divided into two groups using a single-masked randomized allocation method. The experimental group (psyllium husk group) will consume 10 grams of psyllium husk daily, split into two doses, taken about an hour before meals. The control group will receive standard treatment. The intervention will last for 12 weeks.
Inclusion criteria involve a schizophrenia diagnosis as per DSM-V criteria, age between 20 and 65 years, and a body mass index (BMI) of 24 kg/m² or higher, or meeting more than three indicators of metabolic syndrome. Exclusion criteria include medications for glucose, blood pressure, or lipid levels reduction, significant comorbidities like cardiovascular diseases or cancer, a history of neurogenic bowel obstruction or post-weight loss surgery, and patients with severe psychiatric symptoms impeding cooperation.
Each patient will undergo measurements for weight, waist circumference, body mass index, and blood biochemical analysis, encompassing fasting blood glucose (FBG), total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and glycated hemoglobin (HbA1c) before the intervention and after 12 weeks.
Detailed description
The study adopts a quasi-experimental research design and plans to include 24 hospitalized patients with schizophrenia from 2 hospitals in the central region, based on G Power calculations. This study will be matched based on gender, age (within 10 years), and the same hospital.The participants will be divided into two groups using a single-masked randomized allocation method. The experimental group (psyllium husk group) will consume 10 grams of psyllium husk daily, divided into two doses, and taken approximately one hour before meals. The control group will receive standard treatment, and the intervention will last for 12 weeks. Inclusion criteria are: 1. Diagnosis of schizophrenia based on DSM-V criteria; 2. Age between 20 and 65 years old; 3. Body mass index (BMI) of 24 kg/m² or higher or those who meet more than three indicators of metabolic syndrome. Exclusion criteria are medications for lowering blood glucose, blood pressure, or lipid levels, significant comorbidities such as cardiovascular diseases or cancer, history of neurogenic bowel obstruction or post-weight loss surgery, and patients with prominent psychiatric symptoms who cannot cooperate. Each patient will undergo measurements of weight, waist circumference, body mass index, and blood biochemical analysis data, including fasting blood glucose (FBG), total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and glycated hemoglobin (HbA1c) before the intervention and after 12 weeks
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (care provider)
- Number of arms
- 2
- Model description
- . This study will be matched based on gender, age (within 10 years), and the same hospital.The participants will be divided into two groups using a single-masked randomized allocation method. The experimental group (psyllium husk group) will consume 10 grams of psyllium husk daily, divided into two doses, and taken approximately one hour before meals. The control group will receive standard treatment, and the intervention will last for 12 weeks. Inclusion criteria are: 1. Diagnosis of schizophrenia based on DSM-V criteria; 2. Age between 20 and 65 years old; 3. Body mass index (BMI) of 24 kg/m² or higher or those who meet more than three indicators of metabolic syndrome. Exclusion criteria are medications for lowering blood glucose, blood pressure, or lipid levels, significant comorbidities such as cardiovascular diseases or cancer, history of neurogenic bowel obstruction or post-weight loss surgery, and patients with prominent psychiatric symptoms who cannot cooperate.
| Arm | Type | Receives |
|---|---|---|
| Psyllium group | Experimental | Dietary Supplement: psyllium huskThe experimental group (psyllium husk group) will consume 10 grams of psyllium husk daily, divided into two doses, and taken approximately one hour before meals for 12 weeks. |
| Control group | No intervention | –The control group will receive standard treatment, not use psyllium and the intervention will last for 12 weeks. |
Who may qualify
- Ages
- 20 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Diagnosis of schizophrenia based on DSM-V criteria;
- Age between 20 and 65 years old
- Body mass index (BMI) of 24 kg/m² or higher or those who meet more than three indicators of metabolic syndrome
- Individuals with glycated hemoglobin (HbA1c) levels ranging from 5.7% to 6.4%.
Key exclusion criteria (5 listed)
- Exclude those who use blood sugar-lowering, blood pressure-lowering, and blood-lipid-lowering drugs.
- Patients with major internal and external diseases such as cardiovascular disease, cancer, patients who have experienced neuropathic intestinal obstruction, patients after bariatric surgery, or those who have experienced choking.
- Those with obvious mental symptoms who are unable to cooperate.
- History of grain allergy, asthma, etc.
- Persons subject to a declaration of auxiliary guardianship.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| psyllium huskPsyllium husk, derived from the seeds' husks of the Plantago ovata plant, is a plant-based fiber supplement. | Dietary supplement | Psyllium group |
Primary outcome
Body Weight in Kilograms
Time frame: At baseline (week 0) and at weeks 6 and 12 of the study.
Measure body weight in the morning after waking up, with participants wearing light clothing and no shoes.
Waist Circumference in cm
Time frame: At baseline (week 0) and at weeks 6 and 12 of the study.
Waist circumference will be measured to evaluate the impact of psyllium husk intervention on abdominal fat distribution in patients with schizophrenia. Measurements will be conducted using a flexible, non-stretchable measuring tape, positioned horizontally around the abdomen at the midpoint between the lower margin of the last palpable rib and the top of the iliac crest. Participants will stand upright, with feet close together, arms at their sides, and abdomen relaxed during the measurement. The values will be recorded in centimeters (cm). The experimental group will consume 10 grams of psyllium husk daily, while the control group will receive standard treatment. Changes in waist circumference will be analyzed within and between groups."
Body Mass Index (BMI) in (kg/m²)
Time frame: At baseline (week 0) and at weeks 6 and 12 of the study.
Body mass index (BMI) will be calculated to evaluate the impact of psyllium husk intervention on overall body composition in patients with schizophrenia. BMI is expressed in kilograms per square meter (kg/m²) and will be calculated using the formula: weight (kg) divided by height squared (m²). Weight will be measured with a calibrated digital scale, ensuring participants wear light clothing and no shoes. Height will be measured using a wall-mounted stadiometer, with participants standing barefoot, heels together, arms at their sides, and head positioned in the Frankfurt horizontal plane. These measurements will be used to calculate BMI, which will be recorded and analyzed for changes within and between groups.
1 secondary outcome
Metabolic syndrome indicators ex (Fasting Glucose (mg/dL) Total Cholesterol (mg/dL) Triglycerides (mg/dL) High-Density Lipoprotein Cholesterol (HDL-C, mg/dL) Low-Density Lipoprotein Cholesterol (LDL-C, mg/dL) Glycated Hemoglobin (HbA1c, %)
Time frame: During weeks 0 and 12of the study
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jan 2025.
- Individual participant dataSharing planned: No
Related trials for Overweight and Obesity
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mei-Ling Lin study director
HungKaungUniversity
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing psyllium husk in people with Overweight and Obesity and Metabolic Cardiovascular Syndrome, run by Ru-Shin Zhang at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Body Weight in Kilograms (time frame: At baseline (week 0) and at weeks 6 and 12 of the study.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jan 2025.